The place of antagonists of mineralocorticoid receptors in the treatment of chronic heart failure
- Authors: Orlova N.V1, Spiryakina Y.G1
-
Affiliations:
- N.I.Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation
- Issue: Vol 20, No 10 (2018)
- Pages: 36-40
- Section: Articles
- URL: https://journals.rcsi.science/2075-1753/article/view/95070
- DOI: https://doi.org/10.26442/2075-1753_2018.10.36-40
- ID: 95070
Cite item
Full Text
Abstract
Chronic heart failure is the modern epidemic. The article discusses the use of antagonists of mineralocorticoid receptors as drugs that improve the survival and quality of life of patients with chronic heart failure, discusses the possible complexity of the appointment, the ways to overcome them, the choice of a particular drug and the possibility of increasing patient adherence to treatment.
Full Text
##article.viewOnOriginalSite##About the authors
N. V Orlova
N.I.Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation
Email: janezo@yandex.ru
д-р мед. наук, проф. каф. поликлинической терапии лечебного фак-та 117997, Russian Federation, Moscow, ul. Ostrovitianova, d. 1
Ya. G Spiryakina
N.I.Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federationканд. мед. наук, доц. каф. поликлинической терапии лечебного фак-та 117997, Russian Federation, Moscow, ul. Ostrovitianova, d. 1
References
- Roger V.L. Epidemiology of heart failure. Circ Res 2013; 113 (6): 646-59.
- Мареев В.Ю., Фомин И.В., Агеев Ф.Т. и др. Клинические рекомендации. Хроническая сердечная недостаточность (ХСН). Сердечная недостаточность. 2017; 18 (1): 3-40.
- Pitt B, Zannad F, Remme W.J et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure: Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709-17.
- Prabhash C Manoria, Pankaj Manoria, Nidhi Mishra. Angiotensin Receptor Neprilysin Inhibitor for the Treatment of Cardiovascular Diseases: A New Approach. Hypertension 2016; 2 (3): 145-52.
- Duprez D, De Buyzere M, Rietzschel E.R et al. Aldosterone and vascular damage. Curr Hypertens Rep 2000; 2: 327-34.
- Weber K.T, Brilla C.G. Pathological hypertrophy and cardiac interstitium: fibrosis and renin-angiotensin-aldosterone system. Circulation 1991; 83: 1849-65.
- Chai W, Garrelds I.M, de Vries R et al. Nongenomic effects of aldosterone in the human heart: Interaction with angiotensin II. Hypertension 2005; 46: 701-6.
- Sato A, Saruta T. Aldosterone escape during angiotensin converting enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy. J Int Med Res 2001; 29: 13-21.
- Pitt B, Remme W, Zannad F et al. Eplerenone, aselective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309-21.
- Zannad F, McMurray J.J.V, Henry Krum H et al. for the EMPHASIS-HF Study Group. Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms. N Engl J Med 2011; 364: 11-21.
- Dev S, Hoffman T.K, Kavalieratos D et al. Barriers to Adoption of Mineralocorticoid Receptor Antagonists in Patients With Heart Failure: A Mixed-Methods Study. Am Heart Assoc 2016; 5: e002493
- Curtis L.H, Mi X, Qualls L.G et al. Transitional adherence and persistence in the use of aldosterone antagonist therapy in patients with heart failure. Am Heart J 2013; 165: 979-86.
- Ponikowski P, Voors A.A, Anker S.D. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Eur Heart J 2016; 37 (27): 2129-200.
